Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Repotrectinib looks promising, but for a real shot at the market the data cannot deteriorate, and a partner needs to be found.
Roche must believe that Blueprint Medicines’ Ret inhibitor pralsetinib has a safety edge over Lilly’s Retevmo.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.